JP2024539872A5 - - Google Patents
Info
- Publication number
- JP2024539872A5 JP2024539872A5 JP2024522407A JP2024522407A JP2024539872A5 JP 2024539872 A5 JP2024539872 A5 JP 2024539872A5 JP 2024522407 A JP2024522407 A JP 2024522407A JP 2024522407 A JP2024522407 A JP 2024522407A JP 2024539872 A5 JP2024539872 A5 JP 2024539872A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263224P | 2021-10-28 | 2021-10-28 | |
| US63/263,224 | 2021-10-28 | ||
| PCT/US2022/048037 WO2023076485A1 (en) | 2021-10-28 | 2022-10-27 | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539872A JP2024539872A (ja) | 2024-10-31 |
| JP2024539872A5 true JP2024539872A5 (enExample) | 2025-11-05 |
Family
ID=86158503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522407A Pending JP2024539872A (ja) | 2021-10-28 | 2022-10-27 | Ｗｅｅ１阻害剤及びｄｎａ損傷応答（ｄｄｒ）阻害剤を含む併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240299395A1 (enExample) |
| EP (1) | EP4422624A4 (enExample) |
| JP (1) | JP2024539872A (enExample) |
| CN (1) | CN118234493A (enExample) |
| TW (1) | TW202333729A (enExample) |
| WO (1) | WO2023076485A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097139A1 (en) | 2019-11-15 | 2021-05-20 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| KR20230038523A (ko) | 2020-07-09 | 2023-03-20 | 리커리엄 아이피 홀딩스, 엘엘씨 | Wee1 억제제의 염 및 형태 |
| JP2024526203A (ja) * | 2021-06-23 | 2024-07-17 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｗｅｅ１阻害剤、及びがんを治療するための方法 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| WO2025186213A1 (en) * | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721284A (zh) * | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
-
2022
- 2022-10-27 TW TW111140882A patent/TW202333729A/zh unknown
- 2022-10-27 JP JP2024522407A patent/JP2024539872A/ja active Pending
- 2022-10-27 EP EP22888179.3A patent/EP4422624A4/en active Pending
- 2022-10-27 WO PCT/US2022/048037 patent/WO2023076485A1/en not_active Ceased
- 2022-10-27 CN CN202280066997.3A patent/CN118234493A/zh active Pending
-
2024
- 2024-04-26 US US18/648,164 patent/US20240299395A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| US7601868B2 (en) | Amine derivative | |
| JP2024520630A5 (enExample) | ||
| US20260102382A1 (en) | Methods for treatment of fibrotic diseases | |
| JP2023514872A5 (enExample) | ||
| JP2004520292A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2013527202A5 (enExample) | ||
| JP2021513981A5 (enExample) | ||
| JP2005533860A5 (enExample) | ||
| MX2013005124A (es) | Estimuladores de la gcs. | |
| US20240059683A1 (en) | Solid forms of an sgc stimulator | |
| WO2016044447A1 (en) | Pyrazole derivatives as sgc stimulators | |
| JP2013531028A5 (enExample) | ||
| JP2009526072A5 (enExample) | ||
| JP6272626B2 (ja) | カンナビノイド受容体媒介性化合物 | |
| CZ20014015A3 (cs) | Pouľití ligandů D3 receptorů dopaminu pro výrobu léčiv pro léčení poruch funkce ledvin | |
| JP2021533152A5 (enExample) | ||
| JP2021530525A (ja) | ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド | |
| TW202333729A (zh) | 組合 | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| US20200172529A1 (en) | Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof | |
| JP2006512321A5 (enExample) | ||
| JP2020510071A (ja) | 特発性肺線維症の治療 | |
| JP2008500378A5 (enExample) |